>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
合并2型糖尿病乳腺癌患者肿瘤组织中FOXC2的表达情况及其临床意义
作者:李大伟 
单位:海南医学院附属医院 内分泌科, 海南 海口 571200
关键词:乳腺癌 2型糖尿病 FOXC2 乳腺癌分子分型 预后 
分类号:R737.9;R587.1
出版年·卷·期(页码):2017·36·第四期(619-623)
摘要:

目的:探讨FOXC2在合并2型糖尿病乳腺癌患者肿瘤组织中的表达情况,并分析其临床意义。方法:选取2013年1月至2015年12月77例合并2型糖尿病乳腺癌患者为实验组,另取80例非2型糖尿病乳腺癌患者作为对照组。手术切取患者肿瘤组织,对一部分标本提取组织RNA,利用反转录-聚合酶链反应(reverse transcription PCR,RT-PCR)技术检测两组患者癌组织中FOXC2 mRNA表达水平;对另一部分标本石蜡切片行ER、PR、Her-2、FOXC2免疫组化检测,对比免疫组化FOXC2表达结果与RT-PCR结果的一致性。比较两组乳腺癌分子分型构成比的差异,并做FOXC2表达与三阴乳腺癌(基底细胞样型)的相关性分析。通过Kaplan Meier-plotter法分析FOXC2与乳腺癌患者预后的相关性。结果:RT-PCR结果显示,实验组癌组织FOXC2 mRNA表达水平显著高于对照组(P<0.05)。免疫组化的结果显示,FOXC2的表达水平与RT-PCR结果一致。实验组luminal A型占比为22.1%(17/77),luminal B型为18.2%(14/77),Her-2过表达型为24.7%(19/77),基底细胞样型为35.1%(27/77);对照组luminal A型占比为37.5%(30/80),luminal B型为30.0%(24/80),Her-2过表达型为16.3%(13/80),基底细胞样型为16.3%(13/80)。两组患者luminal A型、luminal B型及基底细胞样型占比差异有统计学意义(P<0.05)。两组患者FOXC2 mRNA表达水平与患者基底细胞样型表型呈显著正相关性(P<0.05)。Kaplan Meier-plotter结果显示,高表达FOXC2乳腺癌患者预后差。结论:FOXC2是2型糖尿病致恶性肿瘤的潜在关键因子。

参考文献:

[1] WILD S,ROGLIC G,GREEN A,et al.Global prevalence of diabetes:estimates for the year 2000 and projections for 2030[J].Diabetes Care,2004,27(5):1047-1053.
[2] GALLAGHER E J,LEROITH D.Diabetes,antihyperglycemic medications and cancer risk:smoke or fire?[J].Curr Opin Endocrinol,2013,20(5):485-494.
[3] 念馨,卫俊杰,苏艳丹,等.内脏脂肪组织FOXC2mRNA表达水平与2型糖尿病的关系[J].中国组织工程研究,2011,15(50):9496-9500.
[4] NIAN X,ZHANG X,WANG Y,et al.Correlations of FOXC2 gene expression and polymorphism with type 2 diabetes mellitus[J].Clin Lab,2016,62(5):781-791.
[5] JIN L Z,YONG X S,WANG Z N,et al.The clinical significance of mesenchyme forkhead 1(FoxC2) in gastric carcinoma[J].Histopathology,2013,62(7):1038-1048.
[6] 王静苗,贾喜花,王晓博,等.FOXC2和E-cad在结肠癌组织中的表达及临床意义[J].临床肿瘤学杂志,2016,21(8):718-721.
[7] ZHENG C H,QUAN Y,LI Y Y,et al.Expression of transcription factor FOXC2 in cervical cancer and effects of silencing on cervical cancer cell proliferation[J].Asian Pac J Cacner Prev,2014,15(4):1589-1595.
[8] HOLLIER B G,TINNIRELLO A A,WERDEN S J,et al.FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer[J].Cancer Res,2013,73(6):1981-1992.
[9] HANDELSMAN Y.Diabetes and cancer-an AACE/ACE consensus statement[J].Endocr Pract,2013,19(5):899-899.
[10] LIU X,CHOI R Y,JAWAD S M,et al.Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells[J].Prostate,2011,71(7):766-777.
[11] CATRINA S B.Impaired hypoxia-inducible factor (HIF) regulation by hyperglycemia[J].J Mol Med,2014,92(10):1025-1034.
[12] BELL E L,EMERLING B M,RICOULT S J,et al.SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production[J].Oncogene,2011,30(26):2986-2996.
[13] ZHAO X,XIN R,RONG Z,et al.Zinc oxide nanoparticles induce oxidative DNA damage and ROS-triggered mitochondria-mediated apoptosis in zebrafish embryos[J].Aquat Toxicol,2016,180(2):56-70.
[14] TEMMING P,TRÖGER B,THONNISSEN S,et al.The effect of hyperglycemia on neonatal immune responses in vitro[J].J Matern Fetal Neonatal Med,2012,25(1):94-98.
[15] BLACK C T,HENNESSEY P J,ANDRASSY R J.Short-term hyperglycemia depresses immunity through nonenzymatic glycosylation of circulating immunoglobulin[J].J Trauma,1990,30(7):832-833.
[16] 章晓燕,贾伟平.FOXC2基因与肥胖[J].国际内分泌代谢杂志,2004,24(3):160-162.
[17] KIM J K,KIM H J,PARK S Y,et al.Adipocyte-specific overexpression of FOXC2 prevents diet-induced increases in intramuscular fatty acyl CoA and insulin resistance[J].Diabetes,2005,54(6):1657-1663.
[18] YANG X,ENERBÄCK S,SMITH U.Reduced expression of FOXC2 and brown adipogenic genes in human subjects with insulin resistance[J].Obes Res,2003,11(10):1182-1191.
[19] RIDDERSTRÅLE M,CARLSSON E,KLANNEMARK M,et al.FOXC2 mRNA Expression and a 5' untranslated region polymorphism of the gene are associated with insulin resistance[J].Diabetes,2002,51(12):3554-3560.
[20] MORTAZAVI F,AN J,DUBINETT S,et al.p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells[J].Mol Cancer Res,2010,8(5):762-774.
[21] PARANJAPE A N,SOUNDARARAJAN R,WERDEN S J,et al.Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties[J].Oncogene,2016,35(46):5963-5976.
[22] NISHIDA N,MIMORI K,YOKOBORI T,et al.FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma[J].Ann Surg Oncol,2011,18(2):535-542.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405984 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364